NCT01648036View on ClinicalTrials.gov

Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

February 28, 2014

Conditions
Septic Shock
Interventions
DRUG

Unfractionated heparin

Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death

DRUG

Dalteparin

Dose 5000 IU, subcutaneous, daily

Trial Locations (9)

R2H 2A6

St. Boniface Hospital, Winnipeg

R3A 1R9

Winnipeg Health Sciences Centre, Winnipeg

B3H 3A7 and B3H 2Y9

Capital Health - Queen Elizabeth II Health Sciences Centre, Halifax

L8L 2X2

Hamilton General Hospital, Hamilton

L8N 4A6

St Joseph's Healthcare Hamilton, Hamilton

K1H 8L6

Ottawa Hospital General Campus, Ottawa

K1Y 4E9

Ottawa Hospital Civic Campus, Ottawa

M5B 1W8

St Michael's Hospital, Toronto

G1J 1Z4

Hopital de l'Enfant-Jesus, Québec

All Listed Sponsors
lead

University of Manitoba

OTHER

NCT01648036 - Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot | Biotech Hunter | Biotech Hunter